Search Results

Northwest Biotherapeutics announced today that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio of dendritic cell technologies and intellectual property (IP).

Northwest Biotherapeutics announced today that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024.

Northwest Biotherapeutics announced today that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the system.

Northwest Biotherapeutics provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company’s DCVax®-L treatment for glioblastoma.

Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”) announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

Northwest Biotherapeutics announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company’s Scientific Advisory Board.

Northwest Biotherapeutics provided an update about its progress toward submission of a Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency in the U.K. for commercial approval of the Company’s DCVax®-L treatment for glioblastoma.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.

Northwest Biotherapeutics announces that it plans to submit a Marketing Authorization Application in the U.K., to the Medicines and Healthcare Products Regulatory Agency, for commercial approval of the Company’s DCVax®-L treatment for glioblastoma.